Skip to content
    Reviews

    Prognostic Value of Platelet Biomarkers in Solid Malignancies: A Systematic Review and Meta-Analysis

    Pathan et alJournal of Thrombosis and Thrombolysis

    Prognostic Value of Platelet Biomarkers in Solid Malignancies: A Systematic Review and Meta-Analysis
    Baseline platelet indices have been investigated as accessible prognostic biomarkers in solid tumors due to the role of platelets in tumor angiogenesis, immune evasion, and metastasis. However, their clinical utility has remained uncertain due to inconsistent comparison directions and cancer type-dependent effects across prior reports.
    This PRISMA 2020-compliant and PROSPERO-registered (CRD420261350460) systematic review and meta-analysis evaluated platelet count (PLT), mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT) in patients with solid malignancies. The primary endpoint for all indices was overall survival (OS), and the secondary endpoint was disease-free survival (DFS) for PLT and PDW. Studies were pooled utilizing Hartung-Knapp random-effects models, with 22 of 29 included studies contributing to the quantitative synthesis.
    Pooled PLT-OS was significantly adverse (HR 1.41, 95% CI 1.11–1.79) after excluding two studies with non-exposure-comparable platelet count estimates; the direction-specific high-versus-low PLT estimate was similarly adverse (HR 1.22, 95% CI 1.04–1.42). PLT-DFS was also significantly adverse (HR 1.51, 95% CI 1.10–2.08). For MPV, high-versus-low values were significantly associated with adverse OS (HR 1.34, 95% CI 1.16–1.55, I² = 0%), though the non-directional pooled MPV-OS estimate was not robust to publication bias (trim-and-fill-adjusted HR 1.05, 95% CI 0.85–1.29). In contrast, associations with OS were not significant for PDW (HR 1.95, 95% CI 0.51–7.43) or PCT (HR 1.55, 95% CI 0.22–10.92), and PDW-DFS was likewise not significant (HR 1.17, 95% CI 0.53–2.59). GRADE certainty was moderate for PLT and MPV, low for PDW, and very low for PCT. Diagnostic evidence was synthesized narratively due to substantial clinical and methodological heterogeneity, with combined biomarker and machine-learning models generally showing better discriminatory performance than standalone platelet indices. The authors note that standardized prospective multicenter studies are required.

    Key Takeaways

    • Elevated baseline platelet count was significantly associated with worse overall survival (direction-specific high-vs-low HR 1.22, 95% CI 1.04–1.42; pooled HR 1.41, 95% CI 1.11–1.79) and adverse disease-free survival (HR 1.51, 95% CI 1.10–2.08).
    • High versus low mean platelet volume was significantly associated with adverse overall survival (HR 1.34, 95% CI 1.16–1.55, I² = 0%), whereas platelet distribution width (HR 1.95, 95% CI 0.51–7.43) and plateletcrit (HR 1.55, 95% CI 0.22–10.92) were not significantly associated with overall survival.
    Read the original sourceJournal of Thrombosis and Thrombolysis